
    
      This study is a 1-year non-randomized clinical trial. Two groups of patients (delayed usual
      care and early intensive care) with diagnosis of rheumatoid arthritis (RA) and with symptoms
      onset of less than 2 years and disease modifying anti-rheumatic drugs (DMARDs) naive will be
      recruited. Remission is reached if patients fulfill the Boolean criteria.
    
  